Black Hawk Acquisition Corporation operates as a special purpose acquisition company, structured to achieve a merger, share exchange, asset acquisition, share purchase, reorganization, or another comparable business combination with one or more businesses. Formed in the Cayman Islands in September 2023, the company successfully completed its initial public offering in March 2024. Black Hawk Acquisition recently entered into a definitive business combination agreement in April 2025 with Vesicor Therapeutics, a biotechnology firm specializing in p53-based cancer treatments. The firm's shareholders have also approved measures to extend the deadline for finalizing this business combination, allowing for monthly extensions until December 2026. The company is headquartered in Danville, California.